Data & Technology

A systematic review determines if adult patients with language barriers are less likely to use the video-based virtual care option, while exploring equity and accessibility gaps when it comes to telehealth.

In the third part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, comments on how mobile and digital solutions can be deployed effectively to close the gap in areas identified as pharmacy deserts.

In order to succeed in today’s outcomes-driven healthcare landscape, pharmaceutical companies must move from traditional sales models to strategic, measurable partnerships with integrated delivery networks (IDNs).

In the second part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, details what the company’s data reveals about the relationship between pharmacy access and broader health disparities in underserved communities.

In the first part of her Pharma Commerce video interview, Maggie McCullough, PolicyMap’s CEO, explains how geospatial mapping can help identify and address emerging pharmacy deserts across the United States.

Potential import taxes on pharma goods entering the United States continue to have effects on the industry in more ways than one.

In the final part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses how uncertainty can help reshape the way organizations prioritize supply chain investments.

In the fourth part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, explains how migrating to cloud-based systems can help overcome this challenge.

In the third part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, comments on the role of automation and GenAI evolving in workforce development.

In the second part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, discusses the common misconceptions supply chain leaders might have around the term, and why the processes around optimization need to change.

In the first part of his Pharma Commerce video interview, Scott Tillman, Logility’s senior vice president of innovation, describes the disparity in organizations utilizing supply-chain specific applications.

This serialization system represents a business imperative that yields significant competitive advantages.

As this medical approach continues to become more widely adopted, the industry must adapt to help provide precise, compliant, temperature-controlled delivery of highly individualized treatments.

Addressing drug shortages requires the industry to embrace innovative advanced manufacturing processes underpinned by real-time data.

In the third part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, dives into the barriers limiting AI and automation’s widespread adoption in R&D.

Ruth Beadle, head, global supply chain, Sanofi, discusses the company’s multi-year effort to build an AI-powered, end-to-end supply chain focused on improving service, resilience, and cost efficiency.

In the second part of his Pharma Commerce video interview, Kevin Dondarski, Deloitte’s life sciences R&D strategy leader, outlines strategies that companies can adopt to help mitigate these increasing costs.

A qualitative study aimed to strengthen systematic repurposing efforts within rare disease nonprofit organizations, while also providing a framework for data-driven drug repurposing.

Ways to reimagine pharma’s operating model and KPIs for commercial success in an AI-driven future.

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, patient-centric care.

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing hidden access barriers, streamlining treatment pathways, and challenging outdated utilization management practices.

Doug Long, VP, industry relations, IQVIA, examines shifting pharmaceutical trends, including specialty growth, biosimilar gaps, reimbursement pressure from GLP-1s, and persistent access challenges.

Claire Riches highlights inefficiencies in the current drug approval process, while outlining the role of payers and insurers in shifting toward data-driven approval framework.

By embracing practical, human-centered use cases, life sciences companies are breaking free from GenAI “pilotitis” and demonstrating how scalable AI solutions can help transform patient care and provider efficiency.

Exploring the importance of contract development and manufacturing organizations in advancing the latest technology for effective delivery of temperature-sensitive medicines.